Iressa

• Iressa (Gefitinib) is a targeted therapy primarily used for non-small cell lung cancer (NSCLC).
• It works by inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase, which is often overactive in certain cancers.
• Treatment with Iressa is typically for patients whose tumors have specific activating EGFR mutations.
• Common side effects include skin rash and diarrhea, while more serious adverse events can occur.
• Close medical supervision and adherence to dosage instructions are crucial during Iressa therapy.

What is Iressa (Gefitinib)?

Iressa (Gefitinib) is an oral medication classified as a tyrosine kinase inhibitor (TKI). It is specifically designed to target and block the activity of the epidermal growth factor receptor (EGFR), a protein found on the surface of some cancer cells that plays a critical role in their growth and division. By inhibiting EGFR, Iressa helps to slow or stop the proliferation of these cancer cells.

This medication is primarily indicated for the treatment of non-small cell lung cancer (NSCLC), particularly in patients whose tumors have specific activating mutations in the EGFR gene. These mutations make the cancer cells highly dependent on the EGFR pathway for their survival and growth, making them susceptible to inhibition by drugs like Gefitinib.

How Does Iressa Work and What Is It Used For?

The mechanism of action for Iressa involves its ability to selectively bind to the adenosine triphosphate (ATP)-binding site of the EGFR tyrosine kinase. This binding prevents the receptor from becoming activated, thereby disrupting the signaling pathways that promote cell growth, proliferation, and survival in cancer cells. This targeted approach minimizes harm to healthy cells compared to traditional chemotherapy, which often affects rapidly dividing cells indiscriminately.

What is Iressa used for is primarily in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults. It is specifically indicated for patients whose tumors have activating mutations of the EGFR-tyrosine kinase, as detected by a validated test. This precision medicine approach ensures that the drug is administered to patients most likely to benefit from its specific mechanism of action.

How does Iressa work by interrupting these crucial signaling pathways, leading to reduced tumor growth and, in some cases, tumor shrinkage. It is taken as a once-daily oral tablet, making it a convenient option for long-term management of the disease, under strict medical supervision.

Iressa Side Effects and Important Drug Information

Like all medications, Iressa can cause side effects, ranging from mild to severe. Patients undergoing treatment with Iressa should be closely monitored by their healthcare provider for any adverse reactions. Understanding Iressa side effects is crucial for managing treatment effectively and ensuring patient safety.

Common side effects often include:

• Skin rash (acne-like)
• Diarrhea
• Nausea and vomiting
• Loss of appetite
• Dry skin
• Hair thinning

More serious, though less common, side effects can occur, such as interstitial lung disease (ILD), liver problems, eye disorders, and gastrointestinal perforation. Patients should report any new or worsening symptoms, especially sudden shortness of breath, cough, fever, or severe abdominal pain, to their doctor immediately.

Regarding Iressa drug information, it is important to note that the dosage is typically 250 mg once daily, taken with or without food. Dose adjustments may be necessary based on individual patient tolerance and the severity of side effects. Iressa can interact with other medications, including certain antifungal agents, antibiotics, and blood thinners, which can affect its efficacy or increase the risk of adverse events. Therefore, patients must inform their healthcare providers about all medications, supplements, and herbal products they are taking. Regular monitoring of liver function, kidney function, and electrolyte levels is often performed during treatment to detect and manage potential complications.